![Kenneth Hillan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kenneth Hillan
Direktor/Vorstandsmitglied bei
SANGAMO THERAPEUTICS, INC.
Vermögen: 21 713 $ am 31.05.2026
Profil
Kenneth J.
Hillan is currently an Independent Director at Sangamo Therapeutics, Inc. since 2020 and a Director at Zymeworks BC, Inc. since 2017.
Formerly, Dr. Hillan was CEO, Director & President-R&D Division at Achaogen, Inc. from 2017 to 2019; Independent Director at Relypsa, Inc. from 2015 to 2016; Independent Director at Zymeworks, Inc. from 2017 to 2024; SVP & Head-Roche Product Development, Asia Pacific at Genentech, Inc. from 2010 to 2011; Member of Roche Group from 1994 to 2011; Head-Therapeutics at 23andMe, Inc. from 2019 to 2021; and Chief Therapeutics Officer at Chrome Holding Co. from 2022 to 2023.
Dr. Hillan earned a doctorate from the University of Glasgow School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.06.2025 | 99 600 ( 0,02 % ) | 21 713 $ | 31.05.2026 |
Aktive Positionen von Kenneth Hillan
| Unternehmen | Position | Beginn |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 11.09.2020 |
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Develops protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases | Direktor/Vorstandsmitglied | 03.02.2017 |
Ehemalige bekannte Positionen von Kenneth Hillan
| Unternehmen | Position | Ende |
|---|---|---|
| ZYMEWORKS INC. | Direktor/Vorstandsmitglied | 08.02.2024 |
| CHROME HOLDING CO. | Corporate Officer/Principal | 08.08.2023 |
23andMe, Inc.
 23andMe, Inc. Medical SpecialtiesHealth Technology Develops DNA analysis test kits | Corporate Officer/Principal | 01.06.2021 |
| ACHAOGEN | Vorstandsvorsitzender | 04.04.2019 |
| RELYPSA INC | Direktor/Vorstandsmitglied | 01.09.2016 |
Ausbildung von Kenneth Hillan
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
85
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Sangamo Therapeutics, Inc.
 Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections | Health Technology |
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Develops protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases | Health Technology |
Roche Group
 Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
23andMe, Inc.
23andMe, Inc. Medical SpecialtiesHealth Technology Develops DNA analysis test kits | Health Technology |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops non-absorbed polymeric drugs for applications in cardiovascular and renal diseases | Health Technology |
University of Glasgow School of Medicine
 University of Glasgow School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
23andMe Holding Co.
 23andMe Holding Co. BiotechnologyHealth Technology Operates as a genetic testing company | Health Technology |
Zymeworks, Inc.
 Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
